TOP HEADLINES

Featured Story

  • Sources: Sun has blueprint for turning Ranbaxy around

    Sun Pharmaceutical execs acknowledge it will be no easy task to repair Ranbaxy Laboratories' damaged reputation with the FDA and the public. But Sun managing director Dilip Shanghvi and his lieutenants came in with a laundry list of actions to be taken quickly to jump-start the process, sources tell Reuters.

Novartis' Alcon opens $160M plant in Singapore

With growing demand for eye drugs in Asia, Novartis' Alcon unit wants to have the capacity to sell into that market. To be able to do that, the company has opened a new plant in Singapore to make a variety of its eye drugs.

Counterfeits of Roche's Herceptin found in EU supply chain

European authorities are warning that vials of Roche's cancer med Herceptin that were stolen in Italy are now showing up across the continent with little or none of its active ingredient.

UPDATED: Bill for California statewide disposal law lands in the trash

Drugmakers have so far been unable to stop an Alameda County, CA, law that requires them to pay for the disposal of unused medicines. They have managed, however, to dissuade lawmakers from making it a statewide requirement.

U.K. starts work on $64M biologics manufacturing center

The U.K. is investing £38 million in its National Biologics Manufacturing Centre, part of the country's "High Value Manufacturing Catapult" effort started several years ago to increase its presence in biologics.

NeoStem adds cell therapy manufacturing capacity with CSC buyout

NeoStem, the New York-based developer and manufacturer of cell therapies, will pick up another California plant with its all-stock acquisition of California Stem Cell, which it announced this week.

MORE NEWS

From Our Sister Sites

FierceBiotech

Zafgen has been turning heads with some jaw-dropping results from its mid-stage studies for a promising new obesity drug. And now the biotech hopes to parlay its eye-catching, if risky, technology...

FierceBiotech

Pfizer has reportedly made overtures offering to buy the struggling pharma giant AstraZeneca for $101 billion, setting the stage for what could be the first megamatchup in pharma land in years.